Growth failure is a recognized feature of the Prader-Willi syndrome (PWS). Despite evidence that hypothalamic dysfunction accompanies the syndrome, the etiology of this growth failure remains controversial because most patients with PWS are obese. In order to contribute to resolution of this controversy, we performed a retrospective analysis of 16 obese and non-obese PWS children. GH deficiency was diagnosed in 12 of the 16 subjects and occurred independently of weight status. All of the non-obese subjects were GH deficient. Of the 4 GH-sufficient children, 2 were moderately obese and 2 were morbidly obese. One of these children had clinical evidence of GH deficiency including a low IGF-1 level. Only one of the children had evidence of GH deficiency and a normal IGF-1 level, a pattern that could be attributable to obesity. We conclude that most short children with PWS have growth hormone deficiency and that this deficiency probably results from hypothalamic dysfunction.

Holm V, Cassidy S, Butler M, et al: Prader-Willi syndrome: Consensus diagnostic criteria. Pediatrics 1993;91:398–402.
Costeff H, Holm V, Ruvalcaba R, Shaver J: Growth hormone secretion in Prader-Willi syndrome. Acta Paediatr Scand 1990;79:1059–1062.
Angulo M, Castro-Magana M, Uy J: Pituitary evaluation and growth hormone treatment in Prader-Willi syndrome. J Pediatr Endocrinol 1991;4:167–173.
Lee P, Wilson D, Rountree L, Hintz R, Rosenfeld R: Linear growth response to exogenous growth hormone in Prader-Willi syndrome. Am J Med Genet 1987;28:865–871.
Cappa M, Grossi A, Borrelli P, et al: Growth hormone (GH) response to combined pyridostigmine and GHRH in patients with Prader-Labhard-Willi syndrome. Horm Res 1993;39:51–55.
Lee J, Kim K, Lee K, et al: Reduced growth hormone response to L-dopa and pyridostigmine in obesity. Int J Obes Relat Metab Disord 1994;18:465–468.
Loche S, Pintor C, Cappa M, et al: Pyridostigmine counteracts the blunted growth hormone response to growth hormone-releasing hormone of obese children. Acta Endocrinol 1989;120:624–628.
Drug and Therapeutics Committee of the Lawson Wilkins Pediatric Endocrine Society: Guidelines for the use of growth hormone in children with short stature. J Pediatr 1995;127:857–867.
Pipes P, Holm V: Weight control of children with Prader-Willi syndrome. J Am Diet Assoc 1973;62:520–524.
Hoffman C, Aultman D, Pipes P: A nutrition survey of and recommendations for individuals with Prader-Willi syndrome who live in group homes. J Am Diet Assoc 1992;92:823–833.
Schoeller D, Levitsky L, Bandini L, Dietz W, Walczak A: Energy expenditure and body composition in Prader-Willi syndrome. Metabolism 1988;37:115–120.
Isaacs R, Gardner D, Baxter J: Insulin regulation of rat growth hormone gene expression. Endocrinology 1987;120:2022–2028.
Volta C, Bernasconi S, Iughetti L, et al: Growth hormone response to growth hormone-releasing hormone (GHRH), insulin, clonidine and arginine after GHRH pretreatment in obese children: Evidence of somatostatin increase? Eur J Endocrinol 1995;132:716–721.
Ghigo E, Mazza E, Imeriale E, et al: Enhancement of cholinergic tone by pyridostigmine promotes both basal and growth hormone (GH)-releasing hormone-induced GH secretion in children of short stature. J Clin Endocrinol Metab 1987;65:452–456.
Celniker A, Chen A, Wert R, Sherman B: Variability in the quantitation of circulation growth hormone using commercial immunoassays. J Clin Endocrinol Metab 1989;68:469–476.
Blethen S, Chasalow F: Use of a two-site immunoradiometric assay for growth hormone (GH) in identifying children with GH-dependent growth failure. J Clin Endocrinol Metab 1983;57:1031–1035.
Rose S, Ross J, Uriarte M, et al: The advantage of measuring stimulated as compared with spontaneous growth hormone levels in the diagnosis of growth hormone deficiency. N Engl J Med 1988;319:201–207.
Spilliotis B, August G, Hung W, Sonis W, Mendelson W, Bercu B: Growth hormone neurosecretory dysfunction. JAMA 1984;251:2223–2230.
Rosenfeld R, Albertsson-Wikland K, Cassorla F, et al: Diagnostic controversy: The diagnosis of childhood growth hormone deficiency revisited. J Clin Endocrinol Metab 1995;80:1532–1540.
Rosenfeld R, Kemp R, Hintz R: Constancy of somatomedin response to growth hormone treatment of hypopituitary dwarfism, and lack of correlation with growth rate. Clin Endocrinol Metab 1981;53:611–617.
Ruvalcaba R, Holm V: Effects of growth hormone in Prader-Willi syndrome. Clin Pediatr 1993;32:292–295.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.